December 21, 2017 07:11 AM ESTUpdated 08:11 AM
Pharma

Mer­ck, Pfiz­er make a late — very late — ar­rival at the SGLT2 par­ty for di­a­betes

John Carroll

Editor & Founder

Mer­ck and Pfiz­er have land­ed an FDA ap­proval to start mar­ket­ing er­tugliflozin, mark­ing a late ar­rival for a ther­a­py that will now go toe-to-toe with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times